A multicentre, prospective, non-randomized, sequential, open-label trial to demonstrate the bioequivalence between intravenous immunoglobulin new generation (IGNG) and standard IV immunoglobulin (IVIG) in adult patients with primary immunodeficiency (PID)

Autor:	Viallard, J.-F. a, ⁎, Brion, J.-P. b, Malphettes, M. c, Durieu, I. d, Gardembas, M. e, Schleinitz, N. f, Hoarau, C. g, Lazaro, E. a, h, Puget, S. i
Zdroj:	In La Revue de médecine interne September 2017 38(9):578-584
Databáze:	ScienceDirect
Externí odkaz:	Zobrazit plný text záznamu Full Text from ScienceDirect